3 May 2019 - PHARMAC has a made a decision to change the distribution arrangements and access criteria for the funding of dasatinib monohydrate (Sprycel) tablets for chronic myeloid leukaemia and acute lymphoid leukaemia from 1 June 2019.

In summary the changes mean:

• dasatinib will be funded subject to a standard Special Authority managed by the Ministry of Health and there will no longer be a requirement for individual patient applications to be made to the CML coordinator at PHARMAC;
• direct distribution of dasatinib to patients or their nominated collection point will cease and dasatinib will instead need to be collected from community pharmacies in the same way as other funded medicines

Read PHARMAC notification